drugset
drugset / Trial / NCT05338515

A Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05338515 ↗

Phase 1 Completed 18 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine how safe and how well tolerated selpercatinib is when given as oral doses to healthy participants. The study will also assess how fast selpercatinib gets into the blood stream and how long it takes the body to remove it. The study will last up to about 6 weeks, inclusive of screening period.

Timeline

Start
2019-02-12
Primary completion
2019-03-12
Completion
2019-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Selpercatinib Small molecule 320 mg Oral
Subject Selpercatinib Small molecule 640 mg Oral
Subject Selpercatinib Small molecule 720 mg Oral

Indications

No indication recorded.